Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Anal Bioanal Chem. 2011 Sep 20;401(9):2793–2803. doi: 10.1007/s00216-011-5367-7

Figure 5.

Figure 5

A sample NMR analysis of a pharmaceutical heparin 1H-NMR and 13C-NMR spectra of heparin #1. The spectra were acquired at 600 MHz on a Bruker Avance Ultrashield 600 MHz (14.1-Tesla) NMR instrument. A. Peak assignments for proton spectrum, a, H1 ANS-(G); b, H1 A3S; c, H1 ANS6x; d, H1 I2S; e, H1 I; f, H5 I2S; g, H1 G; h, H6 ANS6S; i, H2 I2S; j, H6’ ANS6S; k, H3 I2S; l, H4 I2S; m, H5 ANS6S; n, H6 ANS; o, H4 ANS6S; p, H3 ANS6x; q, H2 G, H2 A3S; r, H2 ANS6x; s, acetyl CH3 (A, Glucosamine; I, Iduronic acid; G, Glucuronic acid). B. 13C-spectrum of heparin #1 (20 mg) in 0.5 mL of deuterium oxide.